

Hiroshi Aikata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4027995/publications.pdf>

Version: 2024-02-01

195
papers

5,265
citations

101384

36
h-index

123241

61
g-index

198
all docs

198
docs citations

198
times ranked

7167
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. <i>Nature Genetics</i> , 2016, 48, 500-509.	9.4	596
2	Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 414.	1.4	368
3	Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. <i>Nature Genetics</i> , 2011, 43, 797-800.	9.4	156
4	Balloon-Occluded Retrograde Transvenous Obliteration of Gastric Fundal Varices with Hemorrhage. <i>American Journal of Roentgenology</i> , 2002, 178, 1167-1174.	1.0	142
5	Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, 51-58.	1.8	110
6	The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology</i> , 2007, 42, 663-672.	2.3	88
7	Recent trend of clinical features in patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2012, 42, 368-375.	1.8	82
8	Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 530-536.	1.4	82
9	Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. <i>Journal of Hepatology</i> , 2017, 66, 363-373.	1.8	81
10	Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion. <i>Journal of Vascular and Interventional Radiology</i> , 2001, 12, 847-854.	0.2	74
11	Involvement of <i>Porphyromonas gingivalis</i> in the progression of non-alcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2018, 53, 269-280.	2.3	73
12	Percutaneous radiofrequency ablation as first-line treatment for small hepatocellular carcinoma: Results and prognostic factors on long-term follow up. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 597-604.	1.4	72
13	Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2020, 9, 583-595.	4.2	71
14	Stereotactic body radiotherapy for patients with small hepatocellular carcinoma ineligible for resection or ablation therapies. <i>Hepatology Research</i> , 2015, 45, 378-386.	1.8	68
15	Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2015, 1, 516-534.	2.3	67
16	Evaluation of the mRECIST and α -Fetoprotein Ratio for Stratification of the Prognosis of Advanced-Hepatocellular-Carcinoma Patients Treated with Sorafenib. <i>Oncology</i> , 2012, 83, 192-200.	0.9	66
17	Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2002, 184, 284-290.	0.9	62
18	Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients. <i>Hepatology Research</i> , 2016, 46, 758-764.	1.8	60

#	ARTICLE	IF	CITATIONS
19	Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. <i>Journal of Gastroenterology</i> , 2009, 44, 492-502.	2.3	56
20	Efficacy of rosuvastatin for the treatment of non- α alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. <i>Hepatology Research</i> , 2012, 42, 1065-1072.	1.8	56
21	Pretreatment predictor of response, time to progression, and survival to intraarterial 5-fluorouracil/interferon combination therapy in patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2007, 42, 845-853.	2.3	52
22	Differences in serum microRNA profiles in hepatitis B and C virus infection. <i>Journal of Infection</i> , 2015, 70, 273-287.	1.7	52
23	Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1009-1015.	1.4	52
24	Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. <i>EBioMedicine</i> , 2020, 53, 102659.	2.7	48
25	Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1850-1857.	1.4	45
26	Patients with early recurrence of hepatocellular carcinoma have poor prognosis. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2017, 16, 279-288.	0.6	45
27	The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy. <i>PLoS ONE</i> , 2017, 12, e0182710.	1.1	44
28	Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2019, 97, 75-81.	0.9	44
29	Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2022, 11, 354-367.	4.2	44
30	Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. <i>Hepatology</i> , 2012, 56, 555-566.	3.6	43
31	Levodocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis. <i>Hepatology Communications</i> , 2019, 3, 348-355.	2.0	43
32	Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis. <i>Hepatology Research</i> , 2015, 45, 656-662.	1.8	42
33	Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice. <i>Hepatology Research</i> , 2018, 48, 814-820.	1.8	41
34	Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma. <i>Journal of Digestive Diseases</i> , 2015, 16, 505-512.	0.7	40
35	Role of 3D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2015, 45, 607-617.	1.8	40
36	Hepatectomy after down-staging of hepatocellular carcinoma with portal vein tumor thrombus using chemoradiotherapy: A retrospective cohort study. <i>International Journal of Surgery</i> , 2017, 44, 223-228.	1.1	40

#	ARTICLE	IF	CITATIONS
37	Effects of a 24-week course of interferon- λ therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 5343.	1.4	40
38	Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	40
39	Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. <i>Journal of Gastroenterology</i> , 2019, 54, 291-296.	2.3	39
40	Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma. <i>Journal of Computer Assisted Tomography</i> , 2016, 40, 524-530.	0.5	38
41	Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 507-517.	0.9	38
42	Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00179.	1.3	37
43	Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2008, 43, 550-557.	2.3	36
44	HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study. <i>PLoS ONE</i> , 2013, 8, e84226.	1.1	35
45	Similar effects of recombinant interferon- γ 2b and natural interferon- γ when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 070908015728003-???	1.9	34
46	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis. <i>Oncology</i> , 2018, 94, 215-222.	0.9	33
47	Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. <i>Annals of Surgical Oncology</i> , 2012, 19, 418-425.	0.7	31
48	Small Bowel Abnormalities in Patients with Compensated Liver Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1390-1396.	1.1	30
49	Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients. <i>Hepatology Research</i> , 2014, 44, 740-749.	1.8	29
50	Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. <i>Journal of Hepatology</i> , 2015, 63, 554-563.	1.8	29
51	Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice. <i>Cancers</i> , 2021, 13, 3958.	1.7	29
52	Dynamic computed tomography appearance of tumor response after stereotactic body radiation therapy for hepatocellular carcinoma: How should we evaluate treatment effects?. <i>Hepatology Research</i> , 2013, 43, 717-727.	1.8	28
53	Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non- α or Non- β Hepatocellular Carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2015, 29, 480-484.	0.9	28
54	Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1780-1786.	1.4	28

#	ARTICLE	IF	CITATIONS
55	Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay. <i>PLoS ONE</i> , 2015, 10, e0130022.	1.1	28
56	Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2007, 13, 5188.	1.4	28
57	Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon- α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. <i>Hepatology Research</i> , 2012, 42, 442-453.	1.8	27
58	<i>Wisteria floribunda</i> agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. <i>Journal of Gastroenterology</i> , 2017, 52, 1252-1257.	2.3	27
59	Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2020, 9, 148-155.	4.2	27
60	Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. <i>Hepatology Research</i> , 2020, 50, 885-888.	1.8	27
61	The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy. <i>Journal of Medical Virology</i> , 2019, 91, 650-658.	2.5	26
62	Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib. <i>Oncology</i> , 2020, 98, 787-797.	0.9	26
63	Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy. <i>Journal of Gastroenterology</i> , 2011, 46, 799-808.	2.3	24
64	Treatment strategy for early hepatocellular carcinomas: Comparison of radiofrequency ablation with or without transcatheter arterial chemoembolization and surgical resection. <i>Journal of Surgical Oncology</i> , 2011, 104, 3-9.	0.8	24
65	Transarterial Infusion Chemotherapy Using Cisplatin-Lipiodol Suspension With or Without Embolization for Unresectable Hepatocellular Carcinoma. <i>CardioVascular and Interventional Radiology</i> , 2009, 32, 687-694.	0.9	23
66	Major predictors of portal hypertensive enteropathy in patients with liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 124-130.	1.4	23
67	Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice. <i>Journal of Virology</i> , 2015, 89, 10087-10096.	1.5	23
68	Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 215.	3.5	23
69	Zoledronic acid delays disease progression of bone metastases from hepatocellular carcinoma. <i>Hepatology Research</i> , 2010, 40, 1195-1203.	1.8	21
70	Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report. <i>Hepatology Research</i> , 2016, 46, 944-948.	1.8	21
71	Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection. <i>Journal of Gastroenterology</i> , 2016, 51, 1073-1080.	2.3	21
72	Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring. <i>PLoS ONE</i> , 2018, 13, e0195028.	1.1	21

#	ARTICLE	IF	CITATIONS
73	Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization. <i>Anticancer Research</i> , 2016, 36, 3523-9.	0.5	21
74	The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 619-627.	1.4	20
75	Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes. <i>Virology</i> , 2018, 525, 48-61.	1.1	20
76	Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. <i>Liver Cancer</i> , 2021, 10, 151-160.	4.2	20
77	Combination Therapy of Oral Fluoropyrimidine Anticancer Drug S-1 and Interferon Alpha for HCC Patients with Extrahepatic Metastases. <i>Oncology</i> , 2008, 75, 8-16.	0.9	19
78	Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis. <i>Journal of Gastroenterology</i> , 2013, 48, 847-855.	2.3	19
79	Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1035-1042.	1.4	19
80	Is small-bowel capsule endoscopy effective for diagnosis of esophagogastric lesions related to portal hypertension?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 511-516.	1.4	19
81	Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma. <i>European Radiology</i> , 2015, 25, 3272-3281.	2.3	19
82	Third-Generation Capsule Endoscopy Outperforms Second-Generation Based on the Detectability of Esophageal Varices. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	19
83	Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. <i>Hepatology Research</i> , 2016, 46, E146-53.	1.8	19
84	ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 746-753.	2.3	19
85	Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1834-1841.	1.4	18
86	Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 726-732.	1.4	18
87	Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones. <i>Journal of Infection</i> , 2016, 72, 91-102.	1.7	17
88	Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy. <i>Journal of Gastroenterology</i> , 2018, 53, 107-118.	2.3	17
89	Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival. <i>European Journal of Radiology</i> , 2018, 98, 41-49.	1.2	17
90	Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial. <i>BMC Cancer</i> , 2018, 18, 633.	1.1	17

#	ARTICLE	IF	CITATIONS
91	Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study. <i>BMC Gastroenterology</i> , 2021, 21, 306.	0.8	17
92	Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology. <i>Journal of General Virology</i> , 2017, 98, 1040-1047.	1.3	17
93	Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1117-1122.	1.4	16
94	Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation. <i>Hepatology Research</i> , 2015, 45, 1047-1054.	1.8	16
95	Efficacy of radiofrequency ablation for initial recurrent hepatocellular carcinoma after curative treatment: Comparison with primary cases. <i>European Journal of Radiology</i> , 2015, 84, 1540-1545.	1.2	16
96	Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2017, 52, 504-511.	2.3	16
97	Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 193-204.	1.8	16
98	Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 217-226.	2.3	16
99	Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 867-872.	0.4	16
100	Hypersensitivity Reactions to Transcatheter Chemoembolization with Cisplatin and Lipiodol Suspension for Unresectable Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1219-1225.	0.2	15
101	Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection. <i>Hepatology Research</i> , 2017, 47, 767-772.	1.8	15
102	Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice. <i>Biochemical and Biophysical Research Communications</i> , 2018, 500, 152-157.	1.0	15
103	Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis. <i>Hepatology Research</i> , 2020, 50, 1234-1243.	1.8	15
104	Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	1.4	14
105	Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis. <i>BMC Gastroenterology</i> , 2019, 19, 169.	0.8	14
106	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
107	A case with life-threatening secondary sclerosing cholangitis caused by nivolumab. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 283-287.	0.4	14
108	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13

#	ARTICLE	IF	CITATIONS
109	Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy. <i>Scientific Reports</i> , 2019, 9, 12101.	1.6	13
110	Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients. <i>Hepatology Research</i> , 2020, 50, 1222-1233.	1.8	13
111	Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices. <i>European Journal of Radiology</i> , 2010, 76, 239-245.	1.2	12
112	Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 383-387.	0.4	12
113	The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients. <i>Journal of Gastroenterology</i> , 2017, 52, 366-375.	2.3	12
114	Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1834-1840.	2.5	12
115	Evaluation of Patients with Esophageal Varices After Endoscopic Injection Sclerotherapy Using Multiplanar Reconstruction MDCT Images. <i>American Journal of Roentgenology</i> , 2009, 192, 122-130.	1.0	11
116	Clinical utility of gadoxetate disodium-enhanced hepatic MRI for stereotactic body radiotherapy of hepatocellular carcinoma. <i>Japanese Journal of Radiology</i> , 2015, 33, 627-635.	1.0	11
117	Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. <i>Hepatology Research</i> , 2016, 46, 707-712.	1.8	11
118	Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib. <i>Oncology</i> , 2017, 92, 335-346.	0.9	11
119	Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid. <i>Hepatology Research</i> , 2017, 47, 1053-1060.	1.8	11
120	Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2017, 89, 1963-1972.	2.5	11
121	Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 645-650.	1.4	11
122	Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092205.	1.4	11
123	Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib. <i>Hepatology Research</i> , 2014, 44, 1320-1328.	1.8	10
124	Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1412-1419.	1.4	10
125	Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1. <i>Journal of Infectious Diseases</i> , 2020, 222, 2061-2070.	1.9	10
126	Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases. <i>Hepatology Research</i> , 2016, 46, 1402-1408.	1.8	9

#	ARTICLE	IF	CITATIONS
127	Efficacy and safety of daclatasvir plus asunaprevir therapy for chronic hepatitis C patients with renal dysfunction. <i>Journal of Medical Virology</i> , 2017, 89, 665-671.	2.5	9
128	Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: A pilot study. <i>Antiviral Therapy</i> , 2018, 23, 639-646.	0.6	9
129	PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. <i>Journal of Gastroenterology</i> , 2020, 55, 1162-1170.	2.3	9
130	Surgical treatment for portosystemic encephalopathy in patients with liver cirrhosis: Occlusion of portosystemic shunt in combination with splenectomy. <i>Hepatology Research</i> , 2013, 43, 249-254.	1.8	8
131	The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients. <i>Antiviral Therapy</i> , 2017, 23, 239-248.	0.6	8
132	Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection. <i>BMC Gastroenterology</i> , 2020, 20, 314.	0.8	8
133	Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2020, 98, 727-733.	0.9	8
134	Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 2247.	1.7	8
135	Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1268-1275.	1.1	8
136	Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab. <i>Medicine (United States)</i> , 2021, 100, e27576.	0.4	8
137	Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 320.	1.7	8
138	Transcatheter chemoembolization for unresectable hepatocellular carcinoma and comparison of five staging systems. <i>Hepatology Research</i> , 2010, 40, 1082-1091.	1.8	7
139	Effects of <i>ITPA</i> polymorphism on decrease of hemoglobin during simeprevir, peginterferon, and ribavirin combination treatment for chronic hepatitis C. <i>Hepatology Research</i> , 2016, 46, 1256-1263.	1.8	7
140	Predictive Factors of Portal Hypertensive Enteropathy Exacerbation in Patients with Liver Cirrhosis: A Capsule Endoscopy Study. <i>Digestion</i> , 2018, 98, 33-40.	1.2	6
141	<i>CTL</i> -associated and <i>NK</i> cell-associated immune responses induce different <i>HBV</i> DNA reduction patterns in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1555-1564.	1.0	6
142	Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. <i>Clinical Journal of Gastroenterology</i> , 2019, 12, 341-346.	0.4	6
143	Comparison of intracellular responses between <i>HBV</i> genotype A and C infection in human hepatocyte chimeric mice. <i>Journal of Gastroenterology</i> , 2019, 54, 650-659.	2.3	6
144	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. <i>BMC Cancer</i> , 2021, 21, 668.	1.1	6

#	ARTICLE	IF	CITATIONS
145	Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice. <i>Journal of General Virology</i> , 2019, 100, 1123-1131.	1.3	6
146	Optimal indication of endoscopic retrograde pancreatography-based cytology in the preoperative pathological diagnosis of pancreatic ductal adenocarcinoma. <i>Pancreatology</i> , 2022, 22, 414-420.	0.5	6
147	Balloon-Occluded Retrograde Transvenous Obliteration for Portal-Systemic Encephalopathy due to Superior Mesenteric-Caval Shunt via the Right Gonadal Vein. <i>Internal Medicine</i> , 2007, 46, 1479-1480.	0.3	5
148	Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report. <i>Hepatology Research</i> , 2015, 45, 705-710.	1.8	5
149	Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy. <i>Journal of Medical Virology</i> , 2020, 92, 210-218.	2.5	5
150	Treatment outcomes after splenectomy with gastric devascularization or balloon-occluded retrograde transvenous obliteration for gastric varices: a propensity score-weighted analysis from a single institution. <i>Journal of Gastroenterology</i> , 2020, 55, 877-887.	2.3	5
151	Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 1685-1693.	1.4	5
152	Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy. <i>Oncology</i> , 2021, 99, 327-335.	0.9	5
153	<i>in vitro</i> analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism. <i>Molecular Medicine Reports</i> , 2020, 23, .	1.1	5
154	Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 592-599.	1.4	5
155	Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment. <i>Liver Cancer</i> , 2022, 11, 329-340.	4.2	5
156	Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. <i>Hepatology Research</i> , 2011, 41, 1046-1056.	1.8	4
157	<i>IFNL4</i> polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. <i>Hepatology Research</i> , 2017, 47, E5-E13.	1.8	4
158	The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology</i> , 2017, 52, 253-262.	2.3	4
159	Clinical significance of small bowel villous edema in patients with liver cirrhosis: A capsule endoscopy study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 825-830.	1.4	4
160	Early experience of seven hepatocellular carcinoma cases treated with regorafenib. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 2217-2223.	0.2	4
161	Exacerbation of Portal Hypertensive Enteropathy after Endoscopic Injection Sclerotherapy for Esophageal Varices. <i>Digestion</i> , 2021, 102, 188-196.	1.2	4
162	The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675.	1.1	4

#	ARTICLE	IF	CITATIONS
163	Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis. <i>Hepatology Research</i> , 2018, 48, 264-274.	1.8	3
164	Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 267-270.	0.4	3
165	Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. <i>Internal Medicine</i> , 2020, 59, 941-944.	0.3	3
166	A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 839-843.	0.4	3
167	Comparison of liver disease state progression in patients with eradication of versus persistent infection with hepatitis C virus: Markov chain analysis. <i>Journal of Viral Hepatitis</i> , 2021, 28, 538-547.	1.0	3
168	Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients. <i>Journal of Infection</i> , 2022, 84, 391-399.	1.7	3
169	Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 0, , .	4.2	3
170	The first Japanese case of COACH syndrome. <i>Hepatology Research</i> , 2009, 39, 318-323.	1.8	2
171	Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region. <i>Hepatology Research</i> , 2011, 41, 1126-1131.	1.8	2
172	Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 179-184.	0.4	2
173	Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report. <i>Clinical Journal of Gastroenterology</i> , 2020, 13, 421-427.	0.4	2
174	Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures. <i>Internal Medicine</i> , 2021, 60, 829-837.	0.3	2
175	Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1304-1311.	1.0	2
176	The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis. <i>Journal of Medical Ultrasonics (2001)</i> , 2022, 49, 443-450.	0.6	2
177	Usefulness of multi-detector row computed tomography for management of duodenal varices by emergency balloon-occluded retrograde transvenous obliteration. <i>Clinical Journal of Gastroenterology</i> , 2013, 6, 243-247.	0.4	1
178	Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 400-409.	1.0	1
179	Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2021, 99, 491-498.	0.9	1
180	Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. <i>Internal Medicine</i> , 2021, 60, 2047-2053.	0.3	1

#	ARTICLE	IF	CITATIONS
181	A case of primary hepatic leiomyosarcoma. <i>Acta Hepatologica Japonica</i> , 2019, 60, 358-365.	0.0	1
182	Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL. <i>Journal of Infectious Diseases</i> , 2023, 227, 686-695.	1.9	1
183	Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the <i>ATP8B1</i> Gene. <i>Case Reports in Gastroenterology</i> , 2022, 16, 110-115.	0.3	1
184	Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study. <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
185	Multicentric hepatocarcinogenesis at 6 and 13 years after sustained viral response to hepatitis C virus. <i>Clinical Journal of Gastroenterology</i> , 2012, 5, 204-209.	0.4	0
186	Reply from the authors. <i>Hepatology Research</i> , 2020, 50, 1393-1393.	1.8	0
187	A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system. <i>IDCases</i> , 2021, 23, e01059.	0.4	0
188	A case of successful repeated lusutrombopag administration for thrombocytopenia in a patient with cirrhosis requiring multiple invasive procedures. <i>Acta Hepatologica Japonica</i> , 2021, 62, 136-143.	0.0	0
189	A case of simultaneous hepatocellular carcinoma and cholangiocellular carcinoma in a patient with alcoholic liver injury. <i>Acta Hepatologica Japonica</i> , 2021, 62, 300-309.	0.0	0
190	Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice. <i>Biochemical and Biophysical Research Communications</i> , 2021, 559, 78-83.	1.0	0
191	Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1517-1524.	0.4	0
192	A case of primary hepatic angiosarcoma evaluated by contrast-enhanced ultrasonography. <i>Choonpa Igaku</i> , 2018, 45, 215-221.	0.0	0
193	A patient with chronic hepatitis B who developed hepatocellular carcinoma with hypervascularity in 9 years of close follow-up. <i>Acta Hepatologica Japonica</i> , 2022, 63, 24-34.	0.0	0
194	A patient with polycystic liver disease combined with portal hypertension that died due to bacterial peritonitis as a secondary cause of death. <i>Acta Hepatologica Japonica</i> , 2022, 63, 279-285.	0.0	0
195	Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection. <i>Journal of Gastroenterology</i> , 0, , .	2.3	0